fetal calf serum (Cansera International, Etobicoke Ontario, Canada), 2 mM L-glutamine, 100
108 units/ml of penicillin, and 100 µg/ml of streptomycin at 25ºC. Parasites were harvested in the log 109 phase and suspended in phosphate-buffered saline (PBS), counted using a Neubauer counting 110 chamber (Hirschmann, Germany), and then 10 6 to 1 parasites were prepared from the cultures.
111
Each set of 10 6 to 1 parasites was applied to FTA cards (Whatman, Newton Center, MA, USA),
112
and the coded cards were allowed to air dry and stored at room temperature. Ten to eleven months 113 later, 2.0-mm-diameter discs were punched from each FTA card using a Harris micro-punch tool LAMP assay using one punch of an FTA card template per sample was repeated not more than 157 twice for samples negative in the first LAMP assay in order to achieve gene amplification. 
Sequencing

161
To confirm that the LAMP products had the target sequence, direct sequencing of the LAMP 162 amplicons was performed. The LAMP products were purified using a PCR purification kit 
Results and discussion
173
The LAMP assay could detect all the L. (L.) major (10 6 to 1 parasites) levels from 2.0-mm-
174
diameter FTA cards templates. No amplification was detected in the negative controls.
175
Additionally, the FTA-LAMP assay had high detection sensitivity down to a level of 0.01 176 parasites/µl (Fig. 1A) , which agreed with our previous report using purified DNA as a template 
189
We further evaluated the field-and clinic-applicability of the developed FTA-LAMP using 
194
Particularly important is the fact that in this study LAMP could reliably amplify Leishmania 
